StemCells gains $20M award for Alzheimer's program; GlobeImmune sets terms for $60M IPO;

Conversations on Twitter :

 @FierceBiotech: HGS sharpens ax as restructuring claims 114 jobs. Item | Follow @FierceBiotech

 @JohnCFierce: Five down (as in 5 straight late-stage failures): Another Eli Lilly drug flunks a Phase III test. Article | Follow @JohnCFierce

> The California Institute for Regenerative Medicine has approved an award of up to $20 million for StemCells' ($STEM) work on Alzheimer's disease. The money is intended to fuel pre-clinical work through to a potential IND. Release

> Boulder, CO-based GlobeImmune has set its terms for a proposed IPO. The biotech is looking for a range of $11 to $13 a share in an offering that could raise $60 million. Investors have also indicated a willingness to buy up to $16 million of shares, a strategy that has become an industry standard for developers looking to go public. Story

> The U.K.'s Karus Therapeutics, which is working on inflammatory disease and cancer, has rounded up a $7.6 million venture tranche. The financing was led by new investors SV Life Sciences, New Leaf Ventures, Novo A/S and International Biotechnology Trust with angel investors and the IP Group joining in. Release

> Aileron Therapeutics is expanding into endocrine and metabolic diseases and preparing to launch development of its first stapled peptide drug candidate, ALRN-5281, next year. Release

Pharma News

 @FiercePharma: Jazz Pharma is selling its women's health business to Meda for $95M; 60 jobs to go along--AP. News | Follow @FiercePharma

> Top Warner Chilcott investors to unload 43M shares. Article

> Public Citizen sues FDA over Aricept safety. News

> New Indian price caps would raise another hurdle to Big Pharma. Story

Medical Device News

 @FierceMedDev: Sonitus turns to Europe for the commercial rollout of its new hearing aid. It transmits sound through teeth. Release | Follow @FierceMedDev

 @MarkHFierce: Whites are more likely to be treated with CRT-D therapy than blacks and Hispanics, according to a new study. Article | Follow @MarkHFierce

 @DamianFierce: Hologic has to fork over $4M after losing a patent suit to Smith & Nephew. News | Follow @DamianFierce

> Analysts: Medical device M&A will heat up in 2013. Story

> Study: Ariosa's Down syndrome molecular Dx works well in broader population. Item

Vaccines News

> University of Oklahoma advances work on West Nile vaccine. Item

> Low HPV vaccination rates spur calls for wider use. Article

> Dendritic cells raise questions about cancer vax effectiveness. More

> ImmusanT launches U.S. trial for celiac vax. News

Pharma Manufacturing News

> Sun recalls biosimilar used for treating brain bleeding. More

> Under regulatory cloud, CEO says Novartis must boost quality. Article

> Competitors' manufacturing screw-ups keep Fresenius busy. Story

And Finally… U.S. health officials say that the number of new cases of West Nile disease has spiked to the highest level seen since it first erupted in 1999. Story

 

Suggested Articles

Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. Third Rock is coming, too.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.